Skip to Main Content

Paper Details

Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer.
Nat Cancer
14
2023
BCs, HDAC, HDAC6, HDAC6i, HER2, MBC, anticancer, breast cancer, breast cancers, c-Myc, cancer, cancer cells, histone deacetylase, human, metastatic BC, patients, ricolinostat, ricolinstat, tumor, tumor types
Author NameAffiliation
Mariano J AlvarezColumbia University Irving Medical Center
Mariano J AlvarezInc.
Katherine D CrewWinship Cancer Institute of Emory University
Katherine D CrewWinship Cancer Institute of Emory University
Dawn L HershmanWinship Cancer Institute of Emory University
Andrea CalifanoColumbia University Irving Medical Center
  • 1 - 6

Datasets

Release 1.2